THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 89 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,177,677 | +103.5% | 138,877 | +115.2% | 0.00% | – |
Q1 2024 | $578,816 | -20.2% | 64,528 | 0.0% | 0.00% | – |
Q4 2023 | $725,294 | +36.8% | 64,528 | +5.1% | 0.00% | – |
Q3 2023 | $530,012 | -20.5% | 61,415 | 0.0% | 0.00% | – |
Q2 2023 | $666,353 | 0.0% | 61,415 | 0.0% | 0.00% | – |
Q1 2023 | $666,353 | -8.7% | 61,415 | -5.6% | 0.00% | – |
Q4 2022 | $729,737 | -99.9% | 65,039 | -10.2% | 0.00% | – |
Q3 2022 | $734,320,000 | +11.9% | 72,418 | 0.0% | 0.00% | – |
Q2 2022 | $656,108,000 | -8.2% | 72,418 | -3.1% | 0.00% | – |
Q1 2022 | $714,735,000 | -12.8% | 74,763 | +0.8% | 0.00% | – |
Q4 2021 | $819,401,000 | +71.7% | 74,154 | +15.0% | 0.00% | – |
Q3 2021 | $477,301,000 | -48.6% | 64,500 | +0.9% | 0.00% | – |
Q2 2021 | $928,133,000 | -25.2% | 63,921 | +5.1% | 0.00% | -100.0% |
Q1 2021 | $1,240,806,000 | +14.9% | 60,794 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,080,310,000 | +68.3% | 60,794 | +40.0% | 0.00% | – |
Q3 2020 | $642,083,000 | -29.6% | 43,428 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $911,554,000 | +16.7% | 43,428 | +28.5% | 0.00% | 0.0% |
Q1 2020 | $781,211,000 | -10.6% | 33,804 | +0.1% | 0.00% | 0.0% |
Q4 2019 | $873,969,000 | +67.3% | 33,757 | +25.8% | 0.00% | – |
Q3 2019 | $522,551,000 | +143.7% | 26,825 | +104.3% | 0.00% | – |
Q2 2019 | $214,396,000 | -28.0% | 13,129 | 0.0% | 0.00% | – |
Q1 2019 | $297,635,000 | -42.9% | 13,129 | -35.6% | 0.00% | – |
Q4 2018 | $521,447,000 | -7.6% | 20,377 | +17.9% | 0.00% | – |
Q3 2018 | $564,440,000 | +172.9% | 17,277 | +89.5% | 0.00% | – |
Q2 2018 | $206,819,000 | -6.5% | 9,119 | 0.0% | 0.00% | – |
Q1 2018 | $221,136,000 | -53.6% | 9,119 | -46.6% | 0.00% | – |
Q4 2017 | $476,278,000 | -42.0% | 17,077 | -28.8% | 0.00% | -100.0% |
Q3 2017 | $821,692,000 | -1.0% | 23,998 | +15.2% | 0.00% | 0.0% |
Q2 2017 | $829,708,000 | +235.4% | 20,826 | +210.0% | 0.00% | – |
Q1 2017 | $247,394,000 | +115504.7% | 6,719 | 0.0% | 0.00% | – |
Q4 2016 | $214,000 | -50.9% | 6,719 | -44.1% | 0.00% | – |
Q3 2016 | $436,000 | +59.7% | 12,019 | 0.0% | 0.00% | – |
Q2 2016 | $273,000 | -96.7% | 12,019 | -97.5% | 0.00% | -100.0% |
Q1 2015 | $8,184,000 | +134.6% | 471,712 | +101.7% | 0.01% | +166.7% |
Q4 2014 | $3,488,000 | -34.4% | 233,812 | +1.3% | 0.00% | -40.0% |
Q3 2014 | $5,318,000 | -24.5% | 230,712 | +4.4% | 0.01% | -28.6% |
Q2 2014 | $7,043,000 | – | 220,912 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |